Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arthur J Gallagher & Co / Equity Bottom-Up

<ul><li>Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.</li><li>The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.</li><li>Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.</li></ul>

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.

Arthur J Gallagher & Co - Albertsons Companies: An Insight Into Its Technology

<ul><li>Arthur J.</li><li>Gallagher & Company reported strong performance for the second quarter of 2025, showcasing notable achievements in revenue growth, margin expansion, and continuous double-digit growth in adjusted EBITDAC, continuing a streak into the 21st consecutive quarter.</li><li>The company observed a 16% growth in combined revenue from its Brokerage and Risk Management segments, accompanied by a 5.4% organic revenue growth.</li></ul>

Arthur J.Gallagher & Company reported strong performance for the second quarter of 2025, showcasing notable achievements in revenue growth, margin expansion, and continuous double-digit growth in adjusted EBITDAC, continuing a streak into the 21st consecutive quarter.The company observed a 16% growth in combined revenue from its Brokerage and Risk Management segments, accompanied by a 5.4% organic revenue growth.

Arthur J. Gallagher & Co. Accelerates Integration Playbook for Big-Ticket Acquisitions!

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>On the 28th October 2025, <strong><a href="https://www.smartkarma.com/entities/aub-group-limited" target="_blank" data-smartkarma-citation="entities:11179:1" rel="noopener">AUB Group Limited (AUB AU)</a></strong>, an insurance "matchmaker", announced a NBIO, via a Scheme, from EQT at A$45/share, a ~40% premium to undisturbed.</li>
<li>The share price has consistently traded wide to terms, not just because of the transactions' indicative nature; but EQT's track record on progressing from indicative to firm is not optimum.</li>
<li>This morning AUB announced CVC was teaming up with EQT, at $45/share; and concurrently requested additional due diligence. This has been granted by AUB. </li>
</ul>


On the 28th October 2025, AUB Group Limited (AUB AU), an insurance "matchmaker", announced a NBIO, via a Scheme, from EQT at A$45/share, a ~40% premium to undisturbed.
The share price has consistently traded wide to terms, not just because of the transactions' indicative nature; but EQT's track record on progressing from indicative to firm is not optimum.
This morning AUB announced CVC was teaming up with EQT, at $45/share; and concurrently requested additional due diligence. This has been granted by AUB. 


CVC Joins EQT In Pursuit Of AUB Group (AUB AU)

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/aub-group-limited" target="_blank" data-smartkarma-citation="entities:11179:1" rel="noopener">AUB Group Limited (AUB AU)</a></strong>, which operates a network of insurance "matchmakers", has announced a NBIO, via a Scheme, from EQT @ A$45/share, a ~40% premium to undisturbed.</li>
<li>That indicative price is up from $43/share proposed on the 13th September (but not made public). </li>
<li>AUB's board has opted to open its books to EQT, on an exclusive basis, for six weeks. Tentatively, that expires on or around the 9th December. </li>
</ul>



AUB Group Limited (AUB AU), which operates a network of insurance "matchmakers", has announced a NBIO, via a Scheme, from EQT @ A$45/share, a ~40% premium to undisturbed.
That indicative price is up from $43/share proposed on the 13th September (but not made public). 
AUB's board has opted to open its books to EQT, on an exclusive basis, for six weeks. Tentatively, that expires on or around the 9th December. 


AUB Group (AUB AU) Opens Books To EQT's NBIO

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>In response to an AFR article, <a href="https://www.smartkarma.com/entities/aub-group-limited" target="_blank" data-smartkarma-citation="entities:11179:1" rel="noopener">AUB Group Limited (AUB AU)</a> confirmed that on 26 September, it received a non-binding proposal from <a href="https://www.smartkarma.com/entities/eqt-ab" target="_blank" data-smartkarma-citation="entities:28922:1" rel="noopener">EQT (EQT SS)</a> at A$45.00.</li>
<li>While the offer represents an all-time high, it is arguably light compared to precedent transactions and peer multiples. EQT's history of unsuccessful ASX tilts warrants some caution. </li>
<li>The Board has granted a six-week exclusive due diligence period, which ends on 20 November. The shareholder structure reduces the vote risk. </li>
</ul>


In response to an AFR article, AUB Group Limited (AUB AU) confirmed that on 26 September, it received a non-binding proposal from EQT (EQT SS) at A$45.00.
While the offer represents an all-time high, it is arguably light compared to precedent transactions and peer multiples. EQT's history of unsuccessful ASX tilts warrants some caution. 
The Board has granted a six-week exclusive due diligence period, which ends on 20 November. The shareholder structure reduces the vote risk. 


AUB Group (AUB AU): EQT’s NBIO at A$45.00

United States

Arthur J. Gallagher & Co. and its subsidiaries provide insurance brokerage, risk management, employee benefit, and other related services to clients in the United States and abroad. The Company's principal activity is the negotiation and placement of insurance for its clients. Gallagher also specializes in furnishing risk management services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arthur J Gallagher & Co (AJG US)

Arthur J Gallagher & Co - Albertsons Companies: An Insight Into Its Technology

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious...

Baptista Research

Arthur J. Gallagher & Co. Accelerates Integration Playbook for Big-Ticket Acquisitions!

Arthur J. Gallagher & Company reported strong performance for the second quarter of 2025, showcasing notable achievements in revenue growth,...

Baptista Research

CVC Joins EQT In Pursuit Of AUB Group (AUB AU)

Terms are attractive. Yes - indicative. However, the advent of CVC adds a veneer of confidence terms can be firmed. I'd look to enter around here...

David Blennerhassett

AUB Group (AUB AU) Opens Books To EQT's NBIO

Pricing is attractive.Trading wide to terms. EQT has walked away from at least two other deals in recent years - Iress Ltd and Vocus...

David Blennerhassett

AUB Group (AUB AU): EQT’s NBIO at A$45.00

While the offer represents an all-time high, it is arguably light compared to precedent transactions and peer multiples.

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)